Lymphoma
MONDO:0005062A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
Also known as: lymphoma, lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma, MLYM
5929 clinical trials for this condition and its sub-types, 606 tagged with Lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoma
-
B-cell neoplasm 304 trials · 3,167 incl. sub-types
5 sub-types
- Neoplasm of mature B-cells 14 trials · 2,704 incl. sub-types Sub-types →
- B-cell non-Hodgkin lymphoma 258 trials · 2,054 incl. sub-types Sub-types →
- Lymphoplasmacytic lymphoma 44 trials · 159 incl. sub-types Sub-types →
- Large B-cell lymphoma 101 trials
- High-grade B-cell lymphoma double-hit/triple-hit 14 trials
-
Non-Hodgkin lymphoma 526 trials · 2,897 incl. sub-types
10 sub-types
- B-cell non-Hodgkin lymphoma 258 trials · 2,054 incl. sub-types Sub-types →
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
- T-cell non-Hodgkin lymphoma 98 trials · 410 incl. sub-types Sub-types →
- Lymphoblastic lymphoma 78 trials · 104 incl. sub-types Sub-types →
- Lymphoma, non-Hodgkin, familial 73 trials
- Large-cell immunoblastic lymphoma 9 trials
- Lymphosarcoma 8 trials
- Ocular adnexal lymphoma 4 trials
- Gastric non-hodgkin lymphoma 0 trials · 2 incl. sub-types Sub-types →
- Lung non-Hodgkin lymphoma 0 trials Sub-types →
-
Primary organ-specific lymphoma 0 trials · 329 incl. sub-types
8 sub-types
- Primary cutaneous lymphoma 6 trials · 134 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Primary bone lymphoma 1 trial · 92 incl. sub-types Sub-types →
- Intraocular lymphoma 13 trials
- Primary lymphoma of the conjunctiva 1 trial
- Primary oculocerebral lymphoma 0 trials
- Primary pulmonary lymphoma 0 trials
- Thyroid lymphoma 0 trials Sub-types →
-
Hodgkins lymphoma 262 trials · 326 incl. sub-types
5 sub-types
- Classic Hodgkin lymphoma 147 trials · 149 incl. sub-types Sub-types →
- Nodular lymphocyte predominant Hodgkin lymphoma 5 trials · 6 incl. sub-types Sub-types →
- Lymphoma, Hodgkin, X-linked pseudoautosomal 0 trials
- Lymphoma, Hodgkin, Y-linked pseudoautosomal 0 trials
- Splenic hodgkin lymphoma 0 trials
-
Mediastinal malignant lymphoma 6 trials · 180 incl. sub-types
2 sub-types
- Thymus lymphoma 0 trials · 175 incl. sub-types Sub-types →
- Mediastinal gray zone lymphoma 1 trial
-
Pediatric lymphoma 3 trials · 141 incl. sub-types
3 sub-types
- Childhood acute lymphoblastic leukemia 96 trials · 136 incl. sub-types Sub-types →
- T-cell childhood lymphoblastic lymphoma 4 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
Extranodal nasal NK/T cell lymphoma 51 trials
-
Adult lymphoma 1 trial · 33 incl. sub-types
2 sub-types
-
Eye lymphoma 0 trials · 16 incl. sub-types
5 sub-types
- Intraocular lymphoma 13 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- Primary lymphoma of the conjunctiva 1 trial
- Retina lymphoma 1 trial
- Primary oculocerebral lymphoma 0 trials
-
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma 11 trials · 12 incl. sub-types
1 sub-type
- Mediastinal gray zone lymphoma 1 trial
-
Gastrointestinal lymphoma 0 trials · 7 incl. sub-types
10 sub-types
- Gastric lymphoma 1 trial · 3 incl. sub-types Sub-types →
- Small intestine lymphoma 3 trials Sub-types →
- Liver lymphoma 1 trial Sub-types →
- Colorectal lymphoma 0 trials Sub-types →
- Esophagus lymphoma 0 trials
- Gallbladder lymphoma 0 trials
- Pancreas lymphoma 0 trials Sub-types →
- Splenic manifestation of hairy cell leukemia 0 trials
- Splenic manifestation of prolymphocytic leukemia 0 trials
- Tonsillar lymphoma 0 trials
-
Composite lymphoma 5 trials
-
Heart lymphoma 1 trial
-
Breast lymphoma 0 trials · 1 incl. sub-types
1 sub-type
-
Bladder lymphoma 0 trials
-
Chest wall lymphoma 0 trials
1 sub-type
- Solitary plasmacytoma of chest wall 0 trials
-
Lung lymphoma 0 trials
1 sub-type
- Lung non-Hodgkin lymphoma 0 trials Sub-types →
-
Nasal cavity lymphoma 0 trials
-
Ovarian lymphoma 0 trials
-
Prostate lymphoma 0 trials
-
Retroperitoneal lymphoma 0 trials
-
Tracheal lymphoma 0 trials
-
Ureteral lymphoma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 973 trials in this tab.
-
Softer chemo before stem cell transplant aims to cure blood cancers in frail children
Cure CompletedResearchers test a reduced-toxicity conditioning regimen before allogeneic stem cell transplant in children and young adults with blood cancers. The regimen combines fludarabine, full-dose busulfan, and anti-thymocyte globulin. The trial measures transplant-related mortality at o…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Gentler transplant prep aims to cure tough blood cancers
Cure CompletedResearchers test a reduced-intensity conditioning regimen before allogeneic stem cell transplant in adults with high-risk AML, MDS, or ALL who cannot tolerate standard intensive treatment. The regimen combines clofarabine, busulfan, and thymoglobulin. The trial measures relapse r…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Softer chemo before stem cell transplant aims to save more blood cancer patients
Cure CompletedResearchers test a gentler conditioning regimen before allogeneic stem cell transplantation in adults with blood cancers. The goal is to see if this reduced-toxicity approach lowers the risk of death within the first year after transplant. Participants receive fludarabine, busulf…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Can an immunotherapy combo boost remission in a rare lymphoma?
Cure CompletedThis phase II trial is testing whether adding the immunotherapy drug tislelizumab to a chemotherapy regimen (pegaspargase, gemcitabine, and oxaliplatin) plus radiation can improve outcomes for people with early-stage, intermediate- or high-risk extranodal NK/T-cell lymphoma. The …
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemias
Cure CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
Cure CompletedThis phase 2 trial tests a two-step approach to stem cell transplantation for people with blood cancers. The method separates the infusion of donor lymphocytes from stem cells, aiming to better control the dose and reduce the risk of graft-versus-host disease, a serious complicat…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Can a cancer vaccine train the body to fight advanced tumors?
Cure CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase 1 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Vaccine aims to train immune system against blood cancers
Vaccine CompletedResearchers are testing a vaccine called 3D189 in adults with blood cancers such as acute leukemia, multiple myeloma, non-Hodgkin lymphoma, and higher-risk myelodysplastic syndrome. Participants must be in remission after standard treatment and unable to receive a stem cell trans…
Phase 1 • Sponsor: 3D Medicines • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Does the pfizer vaccine work as well in immunosuppressed people? new study aims to find out
Vaccine CompletedThis study looked at how well the Pfizer mRNA vaccine triggers an immune response in people with weakened immune systems compared to healthy individuals. About 539 adults received two doses of the vaccine, and researchers measured antibody levels and side effects. The goal was to…
Phase 4 • Sponsor: Karolinska University Hospital • Aim: Vaccine
Last updated Jun 27, 2026 08:01 UTC
-
Triple drug combo targets Hard-to-Treat brain lymphoma
Disease control CompletedResearchers are testing a combination of rituximab, acalabrutinib, and durvalumab in adults with primary central nervous system lymphoma, a rare cancer that starts in the brain or spinal cord. The trial enrolls people whose disease has returned or worsened after earlier treatment…
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Elderly cancer patients may benefit from geriatric support
Disease control CompletedThis study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…
Sponsor: Institut Bergonié • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to boost cancer treatment
Disease control CompletedThis early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
Disease control CompletedResearchers are testing a combination of L-DEP chemotherapy (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) and a PD-1 antibody as initial treatment for people with Epstein-Barr virus-positive lymphoma-associated hemophagocytic lymphohistiocytosis, a rare an…
Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Antibody-Guided chemotherapy aims to give relapsed leukemia patients a second shot
Disease control CompletedAdults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment have few options. This phase 2 trial tests whether adding epratuzumab, an antibody that attaches to the CD22 protein found on most of these leukemia cells, to standard chemothera…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Which drug cocktail best primes myeloma for transplant?
Disease control CompletedResearchers compare two three-drug combinations, VTD and VCD, as initial treatment for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Participants receive four cycles of either combination. The trial measures how well each combination re…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple drug combo targets mantle cell lymphoma
Disease control CompletedResearchers are testing a combination of three drugs, obinutuzumab, ibrutinib, and GDC-0199, in people with mantle cell lymphoma. The trial includes patients whose cancer has come back or stopped responding to treatment, as well as those who have not yet received treatment. The g…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug combo improve myeloma treatment for older adults?
Disease control CompletedResearchers are testing a combination of carfilzomib, melphalan, and prednisone in adults over 65 with newly diagnosed multiple myeloma. The trial first aims to find the highest dose of carfilzomib that people can tolerate without severe side effects. Then it will measure how wel…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triplet therapy aims to deepen myeloma remission around transplant
Disease control CompletedResearchers are testing whether adding the experimental drug MLN9708 to lenalidomide and dexamethasone can help adults under 66 with newly diagnosed multiple myeloma. Participants receive three cycles of the triplet, then a stem cell transplant, followed by more triplet and maint…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Spinal cages built to fuse bone: can they steady a slipping spine?
Disease control CompletedResearchers are studying a spinal implant called the EVOS Lumbar Interbody System, which uses PEEK-OPTIMA HA enhanced cages, in adults with degenerative disc disease or grade 1 spondylolisthesis in the lower back. The study follows participants who receive the device during spina…
Sponsor: Invibio Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two-Drug combo aims to push CLL into deep remission
Disease control CompletedResearchers are testing whether combining ibrutinib and venetoclax can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial assigns participants to either a fixed course of the two drugs or a course guided by a sensitive test…
Phase 2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for rare skin cancer: targeted antibody tested in china
Disease control CompletedThis study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph no…
Phase 4 • Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Radioactive antibody vs stem cell transplant: which keeps lymphoma at bay?
Disease control CompletedThis phase III trial compares two consolidation treatments for people with relapsed or refractory follicular lymphoma whose cancer has shrunk after chemotherapy. Participants receive either a radioactive antibody called Zevalin or high-dose chemotherapy followed by an autologous …
Phase 3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a common nerve pain drug restore brain chemistry in bipolar cannabis users?
Disease control CompletedThis study tests whether gabapentin, an FDA-approved medication, can help restore the balance of key brain chemicals (GABA and glutamate) in people with bipolar disorder who also use cannabis. Participants are randomly assigned to receive either gabapentin or a placebo for 17 day…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New vaccine aims to shield leukemia patients from COVID-19
Disease control CompletedThis phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can cutting arginine from the diet starve solid tumors?
Disease control CompletedThis phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could flickering lights and tones help fight Alzheimer's? major trial underway
Disease control CompletedThis study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …
Sponsor: Cognito Therapeutics, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Pairing a steroid with lymphoma gel may prevent painful skin reactions
Disease control CompletedThis phase 2 trial tests whether adding triamcinolone 0.1% ointment to Valchlor gel reduces contact dermatitis, a common skin reaction, in people with early-stage cutaneous T-cell lymphoma. Participants apply Valchlor nightly, with or without the steroid up to three times daily, …
Phase 2 • Sponsor: Rochester Skin Lymphoma Medical Group, PLLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill boost Immunotherapy's power against advanced tumors?
Disease control CompletedThis trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…
Phase 1/2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Which lymphoma drug combo works best? a new study aims to find out
Disease control CompletedThis study looks at how well different immunochemotherapy combinations, such as RCHOP, BR, and RCVP, work for people with small B-cell non-Hodgkin lymphoma. Researchers will track 206 adults with this type of lymphoma to see how many respond to treatment and how long they stay fr…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control CompletedThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Four-Drug cocktail tackle Hard-to-Treat myeloma spread?
Disease control CompletedThis phase 2 trial tests a combination of four drugs, selinexor, bortezomib, lenalidomide, and dexamethasone (SVRd), in people newly diagnosed with multiple myeloma whose disease has spread outside the bone marrow, called extramedullary disease. The study aims to see how well thi…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental T-Cell therapy takes aim at lymphoma
Disease control CompletedThis early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), a…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New daily pill shows promise in controlling leukemia
Disease control CompletedThis study tested a daily medication called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL), a type of blood cancer. Participants included those newly diagnosed, those whose cancer returned, and those who had previously taken a similar drug. The goal was to se…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug pair tame hodgkin lymphoma in older patients?
Disease control CompletedThis trial tests whether combining two drugs, brentuximab vedotin (Adcetris) and bendamustine (Levact), can safely and effectively treat Hodgkin lymphoma in people aged 60 to 80 who have not had prior treatment. The standard therapy, ABVD, often causes lung damage in older adults…
Phase 1/2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo shows promise in halting advanced cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a drug combo shrink Hard-to-Treat lymphoma tumors?
Disease control CompletedThis Phase 2 trial tests whether adding venetoclax to ibrutinib can improve complete responses in Japanese adults with mantle cell lymphoma that has returned or not responded to treatment. Participants take both oral drugs for about 104 weeks, then continue ibrutinib alone until …
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new chemo combo outsmart small cell lung cancer?
Disease control CompletedThis trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New 4-Drug cocktail aims to crush myeloma early
Disease control CompletedThis phase 2 study tested a sequence of four drugs—carfilzomib, clarithromycin, lenalidomide, and dexamethasone—in 74 people newly diagnosed with multiple myeloma. The goal was to see how safe and effective this combination is at controlling the disease. Participants first receiv…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted drug combo outsmart brain lymphoma?
Disease control CompletedThis early-stage trial is testing whether adding the targeted drug orelabrutinib to a standard chemotherapy regimen can safely treat newly diagnosed primary central nervous system lymphoma (PCNSL), a rare type of lymphoma that starts in the brain or spinal cord. The study will en…
Phase 1 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo shows promise for rare blood cancer in early trial
Disease control CompletedThis study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat lymphoma tumors?
Disease control CompletedThis phase II trial is testing an experimental drug called BEBT-908 in adults with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The study aims to see how well BEBT-908 shrinks tumors and controls the disease, as well as how s…
Phase 2 • Sponsor: BeBetter Med Inc • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune ce…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis study tested a new combination of drugs for people with Hodgkin lymphoma that either returned after treatment or didn't respond. The goal was to find the safest dose of a targeted drug (brentuximab vedotin) when added to standard chemotherapy. 45 adults took part, and the st…
Phase 1/2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug duo outsmart resistant T-Cell lymphoma?
Disease control CompletedThis phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…
Phase 2 • Sponsor: John Reneau • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
Disease control CompletedThis trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…
Phase 1/2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Multi-Drug combo outsmart resistant lymphoma?
Disease control CompletedThis phase I trial is testing a combination of drugs—avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy—in people with diffuse large B-cell lymphoma or mantle cell lymphoma that has returned or not responded to treatment. The goal is to find the safest dose and see how …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
Disease control CompletedThis phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…
Phase 3 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Lab-Grown stem cells supercharge blood recovery after transplant?
Disease control CompletedThis trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a shorter TB regimen transform child care?
Disease control CompletedThis study looks at how a shorter tuberculosis (TB) treatment regimen works for children and adolescents with non-severe TB in Zambia. It involves children, caregivers, health workers, and policymakers to understand how well the regimen is accepted, followed, and feasible in real…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase 1/2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Triple-Drug combo tame an aggressive lymphoma without harsh chemo?
Disease control CompletedThis phase 2 trial is testing whether a combination of three drugs—sintilimab, pegaspargase, and anlotinib—can effectively treat stage IV extranodal NK/T-cell lymphoma in patients who are not healthy enough for high-intensity chemotherapy. The study enrolls adults with newly diag…
Phase 2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Three-Drug cocktail boost Radiation's power against a rare lymphoma?
Disease control CompletedThis trial is testing whether combining three drugs—camrelizumab, apatinib, and pegaspargase—with radiation therapy can improve outcomes for people with early-stage natural killer/T-cell lymphoma, a rare type of cancer. The study includes about 61 patients with stage IE or IIE di…
Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a targeted drug boost stem cell transplant success in lymphoma?
Disease control CompletedThis trial tests whether adding the targeted drug venetoclax to standard BEAM chemotherapy before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory Non-Hodgkin lymphoma. Venetoclax works by blocking a protein that helps cancer cells su…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart drug missile tame Hard-to-Treat leukemia?
Disease control CompletedThis trial is investigating whether a targeted drug called CMC-544 (inotuzumab ozogamicin), given alone or later combined with rituximab, can control acute lymphoblastic leukemia (ALL) that has returned or not responded to standard treatment. The study enrolls adults and older ch…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a targeted drug boost standard chemo for an aggressive lymphoma?
Disease control CompletedThis phase 2 trial is investigating whether adding the targeted drug copanlisib to the standard R-CHOP chemoimmunotherapy regimen can help people with previously untreated diffuse large B-cell lymphoma (DLBCL) live longer without their cancer progressing. The study enrolls adults…
Phase 2 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a cancer drug's real-world performance match clinical trial results?
Disease control CompletedThis study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…
Sponsor: Sanofi • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted antibody boost chemotherapy against a rare leukemia?
Disease control CompletedThis study tests whether adding a targeted drug called brentuximab vedotin to standard chemotherapy can help people with adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive blood cancer. The combination, known as BV-CHEP, aims to improve response rates by targeting a mar…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase 1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase 1/2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use p…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a diet and exercise program help childhood leukemia survivors live healthier?
Disease control CompletedThis trial tests whether a personalized diet and exercise program, delivered by phone and online, can help adult survivors of childhood leukemia who are overweight or obese lose weight. Participants are randomly assigned to either the active coaching program or a self-directed ap…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A smartphone app may help young cancer survivors get fitter — a trial puts it to the test
Disease control CompletedThis phase 3 trial tests whether a web-based physical activity program, including a wearable tracker and interactive app, can improve fitness and long-term health in children and adolescents who have completed cancer treatment. Participants are randomly assigned to receive either…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a pill tame a common blood cancer in the real world?
Disease control CompletedThis study follows about 269 people with chronic lymphocytic leukemia (CLL) who are starting venetoclax, a targeted pill. Researchers will track how well the drug shrinks or controls the cancer over the first year, and how long it takes before patients need another treatment. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase 1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
Disease control CompletedThis phase 2 trial tests a personalized approach for people with newly diagnosed, advanced classical Hodgkin lymphoma. After two cycles of standard chemotherapy, patients are grouped based on a PET scan. Those with a moderate response receive the immunotherapy drug sintilimab plu…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
Disease control CompletedThis study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will mon…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells show promise against Hard-to-Treat lymphoma
Disease control CompletedThis study tested a treatment called tisagenlecleucel, a type of CAR-T cell therapy, in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Phase 1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase 1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lymphoma in early human test
Disease control CompletedThis early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …
Phase 1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase 1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase 1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase 2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
Disease control CompletedThis Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control CompletedThis phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control CompletedThis study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…
Phase 1/2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
Disease control CompletedThis large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered stem cells aim to speed recovery in blood cancer patients
Disease control CompletedThis trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…
Phase 3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase 1/2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to deepen remission in multiple myeloma
Disease control CompletedThis phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…
Phase 2 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Herbal ointment shows promise for eczema relief
Disease control CompletedThis completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…
Sponsor: VinUniversity • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows early promise for recurrent lymphoma
Disease control CompletedThis early-phase trial tested two drugs, lenalidomide and idelalisib, in 8 people with follicular lymphoma that had returned after previous treatment. Lenalidomide helps the immune system fight cancer, while idelalisib blocks enzymes that cancer cells need to grow. The main goal …
Phase 1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase 1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may shield cancer Patients' hearts from chemo damage
Disease control CompletedThis study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…
Phase 1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for elderly lymphoma patients: a gentler treatment that preserves independence
Disease control CompletedThis phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody combo aims to tackle Hard-to-Treat multiple myeloma
Disease control CompletedThis trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…
Phase 1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New oxygen test could cut unnecessary blood transfusions after heart surgery
Disease control CompletedThis study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase 2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis Phase 3 trial tested whether the CAR-T cell therapy tisagenlecleucel works better than standard treatments for adults with aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to initial therapy. The study enrolled 330 participants and compared how long th…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New chemo cocktail shows promise in myeloma stem cell transplants
Disease control CompletedThis phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Old drug, new hope for rare skin cancer?
Disease control CompletedThis study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Phase 1/2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThis phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New transplant strategy shows promise for blood cancer relapse
Disease control CompletedThis study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase 1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lymphoma combo shows promise in major trial
Disease control CompletedThis large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New dosing strategy aims to tame eye side effects in myeloma drug
Disease control CompletedThis study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase 2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThis study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…
Phase 1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune booster after transplant shows promise for blood cancer patients
Disease control CompletedThis early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink lymphoma with less radiation
Disease control CompletedThis study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination…
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktails show promise for multiple myeloma patients
Disease control CompletedThis study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…
Phase 2 • Sponsor: Mario Boccadoro • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail may boost stem cell transplant success in blood cancer
Disease control CompletedThis study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to crush myeloma early
Disease control CompletedThis phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…
Phase 2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo tackles aggressive lymphoma in large trial
Disease control CompletedThis Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…
Phase 3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma in landmark trial
Disease control CompletedThis study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecti…
Phase 1/2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a new drug combo boost transplant success in lymphoma?
Disease control CompletedThis study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 1…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for lymphoma patients who Can't handle standard chemo
Disease control CompletedThis study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another commo…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cell transplant vs. drugs: which works better for younger myeloma patients?
Disease control CompletedThis study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Weekly carfilzomib combo shows promise for elderly myeloma patients
Disease control CompletedThis phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can lenalidomide keep myeloma at bay after transplant?
Disease control CompletedThis phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hard-to-treat myeloma patients?
Disease control CompletedThis study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to tackle tough myeloma cases
Disease control CompletedThis study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell hope for leukemia patients
Disease control CompletedThis study looked at whether a stem cell transplant can help people under 65 with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. 241 participants received either standard treatment or a transplant. The main goal was to see how long th…
Phase 3 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a drug combo overcome resistance in multiple myeloma?
Disease control CompletedThis study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail aims to wipe out CLL early
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Coaching lowers blood pressure in kidney patients
Disease control CompletedThis study tested whether an educational worksheet plus health coaching could help people with chronic kidney disease improve their blood pressure. 320 adults with moderate to severe kidney disease and uncontrolled high blood pressure took part. The goal was to see if the coachin…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can kids with cancer stop antibiotics sooner? new trial investigates
Disease control CompletedThis study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…
Phase 4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New lens implant could sharpen vision for kids with cataracts and astigmatism
Disease control CompletedThis study tested a toric intraocular lens implant in 40 children aged 6 to 17 with cataracts and astigmatism (a condition where the eye is shaped like a football). The goal was to see if this special lens could improve vision better than standard surgery. All children had catara…
Sponsor: Kazakh Eye Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase 1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Head-to-Head chemo battle: which regimen works better for hodgkin lymphoma?
Disease control CompletedThis Phase 3 trial tested two chemotherapy combinations—BEGEV and GDP—in 88 adults with relapsed or refractory classical Hodgkin lymphoma. Patients received either regimen in 21-day cycles, and their response was checked with a PET scan after three cycles. Those who achieved at l…
Phase 3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Chemo-Free combo shows promise in CLL trial
Disease control CompletedThis phase 3 study tested whether a combination of two targeted drugs, venetoclax and obinutuzumab, works better than standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who lack certain genetic mutations. The main go…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas
Disease control CompletedThis early-phase study tested a new type of cell therapy called ALLO-501, made from donor cells rather than the patient's own cells, in 50 adults with lymphoma that had come back or stopped responding to treatment. The therapy targets CD19, a protein on cancer cells, and was give…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Leukemia drug shows promise in french compassionate use study
Disease control CompletedThis study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, r…
Sponsor: Group for Research in Adult Acute Lymphoblastic Leukemia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that returned or didn't respond to prior treatments. About 217 people took part. The main goal was to see how many patients had their tumors shri…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Tailored treatment shows promise for slowing early dementia
Disease control CompletedThis study tested whether a personalized treatment plan—based on each person's test results—works better than standard care for people with mild cognitive impairment or early-stage dementia. 73 adults aged 45-76 took part, receiving either the tailored plan or usual care for 9 mo…
Phase 3 • Sponsor: Alzheimer's Prevention and Reversal Project, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Stem cell transplant shows promise against rare blood cancer
Disease control CompletedThis study tested whether a stem cell transplant (using the patient's own cells) works better than standard chemotherapy for people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer. 70 patients in China took part. The goal was to see if the transplant c…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a treatment plan using thalidomide, cyclophosphamide, and dexamethasone, followed by long-term thalidomide and prednisone, in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the oral regimen control…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy shows promise for rare blood cancer in younger patients
Disease control CompletedThis study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and …
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare blood cancer: which drug combo works best?
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination better controls the disease and improves survival without progression. Participants received either rituxi…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a pill mop up hidden leukemia cells after chemo?
Disease control CompletedThis study tested the drug ibrutinib in 35 people with chronic lymphocytic leukemia (CLL) who still had small amounts of cancer cells after their first treatment. The goal was to see if ibrutinib could clear those leftover cells from the blood and bone marrow. Participants took i…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
PET scans could spare hodgkin patients from extra chemo
Disease control CompletedThis study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising combo slows myeloma progression in Late-Stage trial
Disease control CompletedThis study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Light-Activated ointment shows promise for rare skin cancer
Disease control CompletedThis study tested a synthetic ointment (HyBryte) activated by visible light to treat mycosis fungoides, a type of skin lymphoma. Ten adults with early-stage disease received treatment for up to 54 weeks. The goal was to see if the ointment could reduce redness, scaling, and plaqu…
Phase 2 • Sponsor: Ellen Kim, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New dosing strategy for myeloma drug shows promise in early trial
Disease control CompletedThis study tested a new way of giving the drug elranatamab to people with multiple myeloma that came back or didn't respond to treatment. The drug was given as a shot under the skin, starting with low doses and then increasing, with longer breaks between doses over time. The goal…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo shows promise for Tough-to-Treat myeloma
Disease control CompletedThis study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Outpatient CAR T-Cell therapy shows promise for tough lymphoma
Disease control CompletedThis study tested a cancer treatment called axicabtagene ciloleucel (a CAR T-cell therapy) given with preventive steroids to 35 adults with large B-cell lymphoma that had returned or not responded to prior treatments. The goal was to see if giving the therapy in an outpatient set…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered T-Cells take on blood cancers in early trial
Disease control CompletedThis early-phase study tested a new type of cell therapy for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T-cells) and added a special…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase 1/2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo aims to keep mantle cell lymphoma in check
Disease control CompletedThis phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase 1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Major trial tests best drug combo for blood cancer control
Disease control CompletedThis study tested different drug combinations in 1,503 adults aged 18-65 with newly diagnosed multiple myeloma. The goal was to see which approach—standard drugs or high-dose chemo with stem cell transplant—works better to delay the cancer's return. Patients received maintenance …
Phase 3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase 1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase 1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Brushing teeth during aplasia: safe or risky?
Disease control CompletedThis study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…
Phase 3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells show promise against stubborn lymphoma
Disease control CompletedThis study tested a one-time treatment using a person's own immune cells, modified to attack cancer, in 159 adults with follicular or marginal zone lymphoma that had returned after at least two prior therapies. The main goal was to see how many patients had their tumors shrink or…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for Hard-to-Treat lymphoma: targeted drug combo shows promise in phase 3 trial
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. The study involved 270 participants and compared the combination to chemotherapy alone. The ma…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy shows promise for Hard-to-Treat myeloma
Disease control CompletedThis phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took…
Phase 3 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Donor stem cell transplant shows promise for myeloma patients under 65
Disease control CompletedThis study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for myeloma patients Who've run out of options?
Disease control CompletedThis phase 2 trial tested a three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 patients with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib to standard chemotherapy could hel…
Phase 2 • Sponsor: University of Leeds • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental CLL drug cirmtuzumab tested for safety in retreatment
Disease control CompletedThis early-phase study tested the safety of cirmtuzumab, an experimental antibody that targets a protein called ROR1 found on CLL cancer cells but rarely on healthy cells. Only 3 people with CLL who had previously received cirmtuzumab were retreated for 6 to 12 months. The main g…
Phase 1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Monthly shot may boost opioid treatment success in hospitals
Disease control CompletedThis study tested whether a once-monthly injection of extended-release buprenorphine helps hospitalized patients with moderate to severe opioid use disorder stay in treatment better than usual care (like daily pills or methadone). Over 300 adults were randomly assigned to receive…
Phase 2/3 • Sponsor: Gavin Bart • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
CAR T-Cell therapy shows promise against tough lymphoma in major trial
Disease control CompletedThis phase 3 trial tested whether a personalized cell therapy called axicabtagene ciloleucel (Yescarta) works better than standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 359 participants and compared event-fre…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Chemo-Free combo shows promise for CLL patients
Disease control CompletedThis phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Chemo-Free hope: new combo aims to outsmart CLL
Disease control CompletedThis phase 2 trial tested a combination of two targeted drugs, venetoclax and ibrutinib, against standard chemotherapy (FCR) in 120 fit patients with intermediate-risk chronic lymphocytic leukemia (CLL). The goal was to see if the drug combo could achieve deep remission with a fi…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for rare blood cancer: lenalidomide dose study shows promise
Disease control CompletedThis study tested the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose by monitoring side effects. Researchers also looked at how many pat…
Phase 1/2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for relapsed myeloma: Triple-Drug cocktail under study
Disease control CompletedThis study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patient…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Real-world data on two-drug combo for hard-to-treat hodgkin lymphoma
Disease control CompletedThis study looked at 222 adults with Hodgkin lymphoma that had returned or not responded to first treatment. Researchers wanted to see how well the combination of brentuximab vedotin and bendamustine worked in everyday medical practice. They measured how long patients stayed free…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene therapy trial targets HIV and lymphoma together
Disease control CompletedThis early-stage study tested a new gene therapy in 2 HIV-positive people with high-risk lymphoma. The therapy involved taking their own stem cells and immune cells, adding a gene to block HIV, and giving them back after chemotherapy. The main goal was to see if the procedure was…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a cheap clot drug save lives in blood cancer patients?
Disease control CompletedThis study tested whether tranexamic acid, a drug that helps blood clot, can lower the risk of serious bleeding or death in people with blood cancers who have dangerously low platelet counts. Over 600 adults receiving chemotherapy or a stem cell transplant were randomly given eit…
Phase 3 • Sponsor: NHS Blood and Transplant • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase 1/2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a smarter chemo schedule help kids beat cancer?
Disease control CompletedThis early-phase trial tested a chemotherapy regimen called DA-EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The drugs are given as a continuous infusion over several days, and doses are adjusted based on how the child's body handles them. The goal wa…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to stall lymphoma without chemo
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug copanlisib to the standard antibody rituximab helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. The study included 458 adults who had already received at lea…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill …
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of ibrutinib and rituximab against other standard drug pairs in 36 people with mantle cell lymphoma that had returned or stopped responding to treatment. The main goal was to check safety and side effects, and to keep giving the treatment to those …
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy offers hope for older leukemia patients
Disease control CompletedThis study tested a new treatment approach for adults over 55 with a specific type of leukemia (B-precursor ALL). The goal was to see if using a targeted drug called blinatumomab along with a reduced dose of chemotherapy could help patients achieve remission with fewer side effec…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Fasting at night may cut cancer risk in people with blood disorder precursors
Disease control CompletedThis study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting p…
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Blood 'bath' with light may stop transplant complication
Disease control CompletedThis study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves removing white blood cells, treating them with a light-sensitive drug and U…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks un…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Pill-and-Antibody combo may replace chemo for common lymphoma
Disease control CompletedThis study tested whether a combination of two drugs (rituximab and lenalidomide) works better than standard chemotherapy plus rituximab for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,030 adults with advanced disease who needed treatment took …
Phase 3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare leukemia: aggressive combo therapy shows promise
Disease control CompletedThis phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients l…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
Double-Dose transplant strategy shows promise for myeloma patients
Disease control CompletedThis study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer pr…
Phase 3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 26, 2026 18:29 UTC
-
New drug cocktail shows promise for relapsed myeloma
Disease control CompletedThis phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and resu…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 13:41 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase 1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Lymphoma trial tests which chemo combo works best for younger patients
Disease control CompletedThis study tested two different chemotherapy regimens (R-CHOP14 and R-ACVBP14), both combined with the drug rituximab, in 222 adults aged 18 to 59 with an aggressive type of B-cell lymphoma. The goal was to see which combination led to a complete response after four cycles of tre…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
Experimental cancer drug PTX-100 enters early human testing
Disease control CompletedThis early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…
Phase 1 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:35 UTC
-
Which scan sees hidden myeloma better: PET or MRI?
Diagnosis CompletedResearchers compare PET scans and MRI to see which imaging method detects more myeloma lesions in adults under 65 with newly diagnosed multiple myeloma. Participants receive both scans at diagnosis, after three cycles of chemotherapy, and at the end of treatment. The study also t…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Could a video call replace the Doctor's office for dementia testing?
Diagnosis CompletedThis study is testing whether a set of memory and thinking tests, usually done in person, can be given remotely over a video call. Researchers will compare results from in-person and remote versions to see if they match. If it works, it could make dementia assessments easier for …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
A simple blood draw might reveal hidden eye lymphoma
Diagnosis CompletedThis study tests whether a blood test can help doctors tell apart uveitis caused by lymphoma from other types of uveitis. Uveitis is an eye inflammation that can lead to vision loss, and in some cases it is a sign of a rare eye lymphoma that may spread to the brain. The researche…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New scan could spot lymphoma without PET
Diagnosis CompletedThis early study tested a new radioactive tracer called 99mTc-1-thio-D-glucose in 16 adults with Hodgkin or non-Hodgkin lymphoma. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it went in the body. The goal was to check safety and whether the …
Phase 1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase 1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New PET tracer shows promise for spotting myeloma bone lesions
Diagnosis CompletedThis study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New imaging agent could sharpen detection of blood cancers
Diagnosis CompletedThis early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…
Phase 1 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Vitamin a boost before stem cell transplant may shield the gut
Prevention CompletedThis trial tests whether a single high dose of vitamin A, given before a donor stem cell transplant, can prevent gastrointestinal graft-versus-host disease (GVHD), a condition where donor cells attack the gut. Vitamin A deficiency is linked to a higher risk of this complication, …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Ancient heat therapy tested to prevent post-transplant bladder pain
Prevention CompletedThis study tests whether moxibustion, a traditional therapy that burns herbs near the skin, can prevent hemorrhagic cystitis (painful bladder inflammation) in 266 patients receiving stem cell transplants. Participants are randomly assigned to receive either standard care or stand…
Sponsor: Yi Zhang • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New vaccine strategy aims to shield lymphoma patients from deadly infections
Prevention CompletedThis study tested a two-step vaccine approach to prevent pneumococcal infections in 26 adults with diffuse large B-cell lymphoma who were receiving chemotherapy with rituximab. The vaccines, Prevenar and Pneumovax, were given in a prime-boost sequence to boost immune protection. …
Phase 3 • Sponsor: University Hospital, Tours • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Diabetes drug shows promise in preventing deadly transplant complication
Prevention CompletedThis study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Could a simple immunization shield cancer patients from severe COVID-19?
Prevention CompletedThis phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an AI chatbot lift the spirits of advanced cancer patients?
Symptom relief CompletedThis trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…
Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can light therapy unblock a common cancer side effect?
Symptom relief CompletedThis trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Could simple education tame myeloma Treatment's harsh side effects?
Symptom relief CompletedThis trial tests whether personalized education from a nurse can help people newly diagnosed with multiple myeloma better handle side effects from the drug bortezomib. Participants receive either standard care or two one-on-one teaching sessions covering symptoms like nerve pain,…
Sponsor: Can Lafci • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Could gratitude exercises aid blood cancer recovery?
Symptom relief CompletedThis trial tests whether a phone-based positive psychology program can improve mood, quality of life, and daily functioning in adults who have just undergone a stem cell transplant for blood cancer. Participants receive weekly calls and complete exercises focused on gratitude, pe…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Could End-of-Life care for blood cancer patients be done at home?
Symptom relief CompletedThis study tests whether a hospital-at-home care model can help people with advanced blood cancers receive end-of-life care at home instead of in the hospital. Participants use remote monitoring and home-based supportive care, with researchers tracking how many enroll and complet…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could kids have upper limb surgery fully awake? new trial tests the idea
Symptom relief CompletedThis trial tests whether a local anesthetic injection (ropivacaine) can keep children aged 6 to 12 awake and comfortable during upper limb surgery, avoiding general anesthesia. Children watch cartoons on a tablet for distraction while the anesthetic is given. The study aims to se…
Phase 4 • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Can a fitness tracker and coaching get teens with leukemia moving?
Symptom relief CompletedThis study tested whether a mobile health program—including a Fitbit with movement reminders, coaching sessions, and a WhatsApp peer support group—could help 20 adolescents and young adults with acute lymphoblastic leukemia (ALL) reduce the time they spend sitting or lying down d…
Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New program helps caregivers of stem cell patients cope better
Symptom relief CompletedThis study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Ancient remedy takes on chemo nerve damage
Symptom relief CompletedThis study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…
Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Fencing fights fatigue: new program aims to keep blood cancer patients moving
Symptom relief CompletedThis study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…
Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Special PE program shows promise for building muscle in teens with intellectual disability
Symptom relief CompletedThis study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…
Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Virtual forests lift mood: VR nature boosts depression treatment
Symptom relief CompletedThis study tested whether adding virtual reality (VR) nature experiences to standard treatment helps adults with mild to moderate depression feel better. 45 participants were split into three groups: one used a high-end VR lab setup, another used a simple self-managed VR, and a c…
Sponsor: Sykehuset Innlandet HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New web tool aims to lighten load for dementia caregivers
Symptom relief CompletedThis study tested a web platform designed for people with mild cognitive impairment or mild to moderate dementia and their primary caregivers. The platform offers social networks, activities, and games to improve quality of life and help them stay in the community longer. Researc…
Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can lotions and gloves soothe cancer therapy's harsh side effects?
Symptom relief CompletedThis study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Phone calls may boost chemo success in leukemia patients
Symptom relief CompletedThis study tested whether weekly nurse phone calls could help people with chronic lymphocytic leukemia (CLL) stick to their chemotherapy plan and reduce side effects. Sixty patients were split into two groups: one received regular care, and the other also got a weekly call to che…
Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Digital coaching eases cancer treatment struggles
Symptom relief CompletedThis study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…
Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Phone therapy eases cancer Survivors' distress in rural areas
Symptom relief CompletedThis study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New lens promises better sight at all distances for cataract patients
Symptom relief CompletedThis study tested a special type of artificial lens (TECNIS Eyhance IOL) in 62 adults aged 45-75 who had cataract surgery. The goal was to see how well the lens helps people see clearly at different distances, from close up to far away. Researchers measured vision at nine distanc…
Sponsor: Democritus University of Thrace • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Simple foot bath may ease chemo fatigue in children
Symptom relief CompletedThis study tested whether a nightly warm foot bath can reduce fatigue in children aged 7-12 with lymphoma who are undergoing chemotherapy. Sixty children took a 20-minute foot bath at 38-40°C for 7 days. The goal was to see if this simple, non-drug approach could improve their en…
Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Teens who beat cancer get stronger with simple strength exercises
Symptom relief CompletedThis study looked at whether 16 weeks of strength training can reduce long-term side effects in teens aged 10-19 who finished treatment for leukemia or lymphoma. Participants did either strength exercises with weights or circuit training with bodyweight and equipment. The goal wa…
Sponsor: Aalborg University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Timing of extra care may boost quality of life in myeloma patients
Symptom relief CompletedThis study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of li…
Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Pumping iron against cancer: exercise may protect muscle during chemo
Symptom relief CompletedThis study tested whether a supervised resistance training program could help lymphoma patients maintain muscle mass and physical function while undergoing chemotherapy. Forty-two adults with newly diagnosed lymphoma were randomly assigned to either the exercise program or usual …
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Laser or ozone: which eases cancer mouth sores best?
Symptom relief CompletedThis study tested two treatments—laser therapy and ozone gas—to relieve painful mouth sores caused by cancer treatment. Forty adults with head and neck or blood cancers took part. Each received one treatment daily for five days. The goal was to see which therapy better reduced so…
Sponsor: University of Pavia • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Heart rate training boosts exercise benefits for cancer survivors
Symptom relief CompletedThis study looked at whether adding heart rate biofeedback training to regular physical activity can improve quality of life for people who have finished treatment for blood cancers. 80 adults in remission took part. The goal was to see if this combination helps them feel better …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Brain tumor insomnia targeted by CBT in new pilot study
Symptom relief CompletedThis study tested a type of talk therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in 70 people with brain tumors who also had trouble sleeping. The therapy involved six weekly group sessions delivered online. The main goal was to see if the approach was practical …
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
HIIT and weights show promise for stem cell recovery
Symptom relief CompletedThis study looked at whether 12 weeks of high-intensity interval training (HIIT) and resistance training could help people who had a stem cell transplant for blood cancer. It involved 16 patients and their caregivers. The goal was to see if exercise improves physical function, th…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Virtual reality goggles may calm chemotherapy patients
Symptom relief CompletedThis study tested whether using augmented virtual reality (AVR) during chemotherapy can help reduce pain, stress, and anxiety while boosting self-confidence. 150 adult cancer patients in the West Bank were split into two groups: one received standard care, and the other used AVR …
Sponsor: Arab American University (Palestine) • Aim: Symptom relief
Last updated Jun 26, 2026 17:13 UTC
-
Can early palliative care ease suffering in relapsed leukemia?
Symptom relief CompletedThis study looked at whether early, regular visits from a palliative care team can improve quality of life for adults with acute leukemia that has returned. 49 patients were assigned to either receive this extra support or standard care. The team addressed physical, emotional, an…
Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 26, 2026 16:57 UTC
-
Empowerment program shows promise for healthier habits in young leukemia patients
Symptom relief CompletedThis study tested a child-centered empowerment program designed to help children with leukemia improve their lifestyle habits, including nutrition, sleep, physical activity, and stress management. Forty-six children aged 7-13 took part, with half receiving the program and half ge…
Sponsor: Near East University, Turkey • Aim: Symptom relief
Last updated Jun 26, 2026 14:44 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Lab tests could pick the right drug for tough myeloma cases
Knowledge-focused CompletedThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists map protein patterns in lymphoma to unlock disease secrets
Knowledge-focused CompletedThis completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
The immune cells that could make stem cell transplants work better
Knowledge-focused CompletedResearchers are studying natural killer (NK) cells in people who receive stem cell transplants for leukemia. The study follows 92 patients and their donors, looking at genes called KIR and HLA that control how NK cells work. By tracking NK cells during immune recovery, researcher…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Preterm Kids' brains tracked to age 9 in new study
Knowledge-focused CompletedThis study follows children born moderately or late preterm (32-36 weeks) to age 9, measuring their thinking, movement, language, behavior, and growth. Researchers compare these kids to full-term peers to understand long-term effects. The goal is to learn how early development pr…
Sponsor: Noordwest Ziekenhuisgroep • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can we predict lung damage from CAR t-cell therapy?
Knowledge-focused CompletedThis study looks back at the medical records of about 266 adults who received CAR T-cell therapy for blood cancers. The goal is to describe lung complications that happen within 30 days or up to 2 years after treatment. Researchers will also look for patient characteristics that …
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can wearables decode the mystery of fatigue?
Knowledge-focused CompletedResearchers are using wearable sensors and smartphone check-ins to track fatigue as it happens in people with myeloma, long COVID, heart failure, and healthy controls. Participants wear an ECG patch and a wrist sensor that measure heart rate, activity, and posture, and they rate …
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Farmers' pesticide use linked to blood cancer precursors
Knowledge-focused CompletedThis study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Eye disease biobank seeks clues to uveitis
Knowledge-focused CompletedThis study collected blood, saliva, and eye fluid samples from 343 people with uveitis, an inflammatory eye disease that can cause vision loss. Researchers aimed to learn which genes and other factors might lead to the disease and affect treatment response. Participants were foll…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Pee and blood may spare patients painful bone marrow needles
Knowledge-focused CompletedThis study looked at 300 people with Waldenström's macroglobulinemia or a related condition to see if blood or urine tests could detect key genetic mutations as accurately as bone marrow biopsies. The goal is to find a less invasive way to monitor the disease over time. Researche…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can a daily mood diary reveal how steroids affect emotions?
Knowledge-focused CompletedThis study follows patients with cutaneous T-cell lymphoma or chronic cluster headache who are receiving corticosteroid treatment as part of their regular care. Participants fill out a short daily questionnaire on their phone for about 40 days, starting a few days before treatmen…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Study aims to uncover hidden hormone failure in ICU patients
Knowledge-focused CompletedThis study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
A 5-minute quiz might predict who gets severe chemo side effects
Knowledge-focused CompletedThis study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can tracking severe asthma over time unlock better treatments?
Knowledge-focused CompletedThis research program aims to deepen understanding of severe asthma by closely studying its clinical and biological features over time. Researchers will follow more than a thousand people with asthma, aged 6 and older, measuring lung function and tracking how often severe asthma …
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can a closer look at bone complications in multiple myeloma improve rehabilitation?
Knowledge-focused CompletedMultiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Rare childhood bone lymphoma: can past cases guide future care?
Knowledge-focused CompletedThis study looks back at 21 children and teens diagnosed with a rare type of lymphoma that starts in the bone. Researchers are collecting medical records to describe how the disease presents, how it was treated, and how well patients did over time. The goal is to learn more about…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Fine-Tuning MRI scanners to sharpen the picture of the brain
Knowledge-focused CompletedThis study uses a research-dedicated 3T MRI scanner to develop and optimize imaging protocols in healthy adults. Researchers aim to reduce image distortions, improve contrast and resolution, and create new sequences for functional MRI. The work will help enable future studies in …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Russian study to monitor Real-World use of acalabrutinib in CLL patients
Knowledge-focused CompletedThis observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Wearable patch and phone app could spot dangerous fevers before they spike in cancer therapy
Knowledge-focused CompletedThis study tests two devices — a wearable temperature patch and a smartphone app that measures vital signs from a facial scan — in adults with blood cancers receiving CAR-T or bispecific T-cell engager therapy. The goal is to see if these tools can detect fevers and other signs o…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New tool could help spot brain issues in At-Risk newborns earlier
Knowledge-focused CompletedThis study is translating and testing a Turkish version of the Hammersmith Neonatal Neurological Examination (HNNE) for high-risk infants, such as premature babies or those with birth complications. Researchers will check if the exam is reliable and valid for use in Turkey by com…
Sponsor: Kahramanmaras Sutcu Imam University • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Exosomes: the decoy receptors that may sabotage lymphoma treatment
Knowledge-focused CompletedThis study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
No new drug, just data: italian study tracks Real-World myeloma care
Knowledge-focused CompletedThis study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Real-World data may reveal best Second-Line therapy for multiple myeloma
Knowledge-focused CompletedThis study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
Knowledge-focused CompletedThis study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…
Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Researchers review CAR T-Cell results in kids with B-ALL
Knowledge-focused CompletedThis study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can scans and blood predict CAR T-Cell success?
Knowledge-focused CompletedThis pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New guide aims to help myeloma patients stick to their pill regimen
Knowledge-focused CompletedThis study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Which drug works better for stem cell collection? study compares zarzio and granocyte
Knowledge-focused CompletedThis completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Hidden danger: why some patients can't shake COVID-19
Knowledge-focused CompletedThis study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…
Sponsor: Maddalena Giannella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study reveals how well COVID vaccines protect myeloma patients
Knowledge-focused CompletedThis study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…
Sponsor: ASH Research Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
What do patients really think? small study asks multiple myeloma survivors about their treatment journey
Knowledge-focused CompletedThis study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New training aims to help doctors catch child abuse earlier
Knowledge-focused CompletedThis study looked at whether a new educational program helps doctors-in-training better recognize and respond to child maltreatment. 84 medical residents from Canadian universities took part. The program was delivered either in a group with a leader or on their own. The goal was …
Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists probe the hidden types of severe childhood asthma
Knowledge-focused CompletedThis completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Iron deficiency in cancer: a hidden problem exposed
Knowledge-focused CompletedThis study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New EHR tool aims to boost Heart-Health talks for cancer survivors
Knowledge-focused CompletedThis study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase 1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Hospital program helps older blood cancer patients plan future care
Knowledge-focused CompletedThis study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New program aims to ease financial burden for young cancer survivors
Knowledge-focused CompletedThis study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Child cancer and birth defects: hidden genetic clues?
Knowledge-focused CompletedThis completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Heart risks during CAR T-Cell therapy under the microscope
Knowledge-focused CompletedThis study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Carbon fiber braces could ease ankle strain, early study suggests
Knowledge-focused CompletedThis study tested custom carbon fiber ankle braces in 9 healthy adults to see how they change forces across the ankle joint. Researchers varied the brace design and used a computer model to estimate joint contact stress. The goal was to improve the model and understand how brace …
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Leukemia Survivors' immunity under the microscope
Knowledge-focused CompletedThis study followed 89 children who finished chemotherapy for acute lymphoblastic leukemia (ALL) to see how their immune systems bounced back. Researchers measured antibody levels for vaccine-preventable diseases and tracked infections during the first year off treatment. The goa…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Liver impairment drug study completed: how golcadomide behaves
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand…
Phase 1 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Gut health under the microscope: new study targets hidden danger in ICU blood cancer patients
Knowledge-focused CompletedThis completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could tiny particles explain clot danger in kids with leukemia?
Knowledge-focused CompletedThis completed study looked at 24 children with acute lymphoblastic leukemia to see if tiny cell fragments called microparticles contribute to dangerous blood clots during treatment. Researchers collected blood samples to measure these particles and a clotting protein on their su…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Needle-Free myeloma monitoring: blood test and MRI show promise
Knowledge-focused CompletedThis study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…
Sponsor: Rajshekhar Chakraborty, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Which donor search strategy saves more lives?
Knowledge-focused CompletedThis study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Blood mutation may reveal hidden lymphoma after treatment
Knowledge-focused CompletedThis study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to mea…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Blood test could replace bone marrow biopsy for rare blood cancer monitoring
Knowledge-focused CompletedThis study looked at 45 adults newly diagnosed with Waldenström's disease, a rare blood cancer. Researchers compared different lab methods to detect a common genetic mutation (MYD88 L265P) in blood and bone marrow samples. The goal was to find less invasive ways to diagnose and t…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Timing tumor DNA tests after chemo: a small study
Knowledge-focused CompletedThis study measured how levels of circulating tumor DNA (ctDNA) change in the hours after the first round of chemotherapy in 24 people with diffuse large B cell lymphoma. The goal was to find the best time to take blood samples for monitoring the cancer. Researchers hope that a b…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Swallow a thermometer? new study tests pill that takes your temperature from inside
Knowledge-focused CompletedThis study tested whether a small, swallowable capsule can accurately measure body temperature in 30 hospitalized patients with blood cancers who have very low immunity (neutropenia). Researchers compared the capsule's temperature readings to standard ear thermometer measurements…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New imaging tracer could reveal how chemotherapy affects lymphoma blood vessels
Knowledge-focused CompletedThis study tested a special PET scan tracer called 18F-RGD-K5 in 21 people with lymphoma. The tracer highlights blood vessel growth (angiogenesis) in tumors. Scans were done before and after two rounds of chemotherapy to see how the tumors changed. The goal was to learn whether t…
Phase 2 • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Do vaccines work as well in people with weak immune systems? new study investigates
Knowledge-focused CompletedThis study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…
Phase 4 • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists create detailed map of Lymphoma's immune environment
Knowledge-focused CompletedThis study looked at 60 people with diffuse large B-cell lymphoma who were starting standard chemotherapy (R-CHOP). Researchers used advanced single-cell technology to analyze tumor and blood samples over two years. The goal was to find biomarkers that could help predict how well…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a machine read pain in silent kids?
Knowledge-focused CompletedThis study tested whether a device called the ANI monitor can measure pain in sedated children aged 2 and older in the pediatric intensive care unit. Researchers watched how the device responded during painful care and compared it to a standard behavioral pain scale. The goal was…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Telemedicine takes on lymphoma: a 350-Patient trial
Knowledge-focused CompletedThis study looked at whether using telemedicine (remote doctor visits) can improve how aggressive lymphomas are managed. The main goal was to see if patients got the right amount of chemotherapy on time. 350 patients from 10 hospitals took part. The study compared telemedicine su…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
CLL patients left in the dark: study maps treatment gaps after key drug fails
Knowledge-focused CompletedThis study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to a class of drugs called BTK inhibitors (like ibrutinib) and, in some cases, also to venetoclax. The goal was to understand what treatments doctors used next and how well the…
Sponsor: French Innovative Leukemia Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Italian study reveals Real-World impact of targeted leukemia drug
Knowledge-focused CompletedThis study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected informa…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Real-World study tracks patient adherence to multiple myeloma drug regimens
Knowledge-focused CompletedThis study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure ad…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood cell study aims to predict transplant complications
Knowledge-focused CompletedThis study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New scan method could improve fungal infection care in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood test may spot bone damage in multiple myeloma
Knowledge-focused CompletedThis study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study observes how patients with mantle cell lymphoma fare on modern drugs
Knowledge-focused CompletedThis study created a registry of 227 adults with mantle cell lymphoma who had recently started a new type of therapy. Researchers tracked which treatments were used, how long patients stayed on them, and how patients rated their own quality of life. The goal was to gather real-wo…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Can we predict who bounces back after a bone marrow transplant?
Knowledge-focused CompletedThis study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Liver function and drug levels: a repotrectinib study
Knowledge-focused CompletedThis study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for pa…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New study tracks clues to predict transplant complication
Knowledge-focused CompletedThis study followed 267 adults who had stem cell transplants to understand why some develop chronic graft-versus-host disease (GVHD), a common complication. Researchers collected blood, saliva, tears, and tissue samples, along with eye scans and breathing tests, to find early sig…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New telemedicine service brings nighttime care to children in ghana
Knowledge-focused CompletedThis study tested a new service that lets parents call for medical help at night and get medicine delivered to their home for their sick children. Over 1,200 children with common illnesses like pneumonia, diarrhea, or malaria took part in three communities in Ghana. The goal was …
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New drug tested in patients with liver disease – safety first
Knowledge-focused CompletedThis study looked at how the drug AZD2389 behaves in people with liver impairment compared to healthy volunteers. 35 adults took a single dose, and researchers measured drug levels in the blood to check safety and processing. The goal is to understand if liver problems change how…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Genetic clues could sharpen lymphoma diagnosis
Knowledge-focused CompletedThis study examined genetic changes in 555 patients with aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma. Researchers used a technique called FISH to look for specific gene rearrangements. The goal was to see if these genetic markers could help classify tumors …
Sponsor: Andrés José Maria Ferreri • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:02 UTC
-
Blood cancer study seeks markers to match patients with best immunotherapy
Knowledge-focused CompletedThis completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:43 UTC
-
PET scans may guide treatment of hidden fungal infection in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of PET scan can help doctors diagnose and treat a rare fungal infection of the liver and spleen in people with blood cancer or those who had a stem cell transplant. The infection often appears after severe neutropenia (low white blood c…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:07 UTC
-
Family DNA hunt aims to uncover myeloma risk genes
Knowledge-focused CompletedThis study collected blood samples from nearly 1,900 people in families where at least two members have a type of dysglobulinemia, including multiple myeloma, MGUS, or Waldenström's disease. Researchers will analyze the DNA to look for genetic variations that might increase the r…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:03 UTC